RESEARCH led by Monash's Centre for Medicine Use and Safety (CMUS) suggests that men and women may need different medications to prevent fractures after a first hip fracture.
The team set out to investigate the risk of fracture and death in people with dementia and frailty prescribed bisphosphonates or denosumab following their first hip fracture, comparing treatment outcomes across a number of studies.
Overall, bisphosphonate users had a 25% higher rate of any subsequent fracture than denosumab users, but men using bisphosphonates rather than denosumab had a lower rate of death.
People with and without dementia appeared to derive similar benefits from each medication, an important finding given that people with dementia are often undertreated with bone strengthening medications.
"We found no significant difference in treatment outcomes in people with or without dementia or frailty," said lead author Associate Professor Jenni Ilomaki.
"We did, however, identify an unexpected sex-related difference," she noted.
"Our hope is that this study is a building block toward better informed practice moving forward," Associate Professor Ilomaki concluded.
Read the study HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Dec 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Dec 25
